|
1
|
Niccoli G, Burzotta F, Galiuto L and Crea
F: Myocardial no-reflow in humans. J Am Coll Cardiol. 54:281–292.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao YJ, Fu XH, Ma XX, Wang DY, Dong QL,
Wang YB, Li W, Xing K, Gu XS and Jiang YF: Intracoronary fixed dose
of nitroprusside via thrombus aspiration catheter for the
prevention of the no-reflow phenomenon following primary
percutaneous coronary intervention in acute myocardial infarction.
Exp Ther Med. 6:479–484. 2013.PubMed/NCBI
|
|
3
|
Chan W, Stub D, Clark DJ, Ajani AE,
Andrianopoulos N, Brennan AL, New G, Black A, Shaw JA, Reid CM, et
al: Melbourne Interventional Group Investigators: Usefulness of
transient and persistent no reflow to predict adverse clinical
outcomes following percutaneous coronary intervention. Am J
Cardiol. 109:478–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Svilaas T, Vlaar PJ, van der Horst IC,
Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun
GA, Tan ES, Suurmeijer AJ and Zijlstra F: Thrombus aspiration
during primary percutaneous coronary intervention. N Engl J Med.
358:557–567. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berger PB and Ryan TJ: Inferior myocardial
infarction. High-risk subgroups. Circulation. 81:401–411. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fu XH, Fan WZ, Gu XS, Wei YY, Jiang YF, Wu
WL, Li SQ, Hao GZ, Wei QM and Xue L: Effect of intracoronary
administration of anisodamine on slow reflow phenomenon following
primary percutaneous coronary intervention in patients with acute
myocardial infarction. Chin Med J (Engl). 120:1226–1231.
2007.PubMed/NCBI
|
|
7
|
Wang Y, Fu X, Wang X, Jia X, Gu X, Zhang
J, Su J, Hao G, Jiang Y, Fan W, et al: Protective effects of
anisodamine on renal function in patients with ST-segment elevation
myocardial infarction undergoing primary percutaneous coronary
intervention. Tohoku J Exp Med. 224:91–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geng W, Fu XH, Gu XS, Wang YB, Wang XC, Li
W, Jiang YF, Hao GZ, Fan WZ and Xue L: Preventive effects of
anisodamine against contrast-induced nephropathy in type 2
diabetics with renal insufficiency undergoing coronary angiography
or angioplasty. Chin Med J (Engl). 125:3368–3372. 2012.PubMed/NCBI
|
|
9
|
Wang YB, Fu XH, Gu XS, Wang XC, Zhao YJ,
Hao GZ, Jiang YF, Fan WZ, Wu WL, Li SQ and Xue L: Safety and
efficacy of anisodamine on prevention of contrast induced
nephropathy in patients with acute coronary syndrome. Chin Med J
(Engl). 125:1063–1067. 2012.PubMed/NCBI
|
|
10
|
Lee HC, An SG, Choi JH, Lee TK, Kim J, Kim
JH, Chun KJ, Hong TJ, Shin YW and Lee SK: Effect of intra-coronary
nicorandil administration prior to reperfusion in acute ST segment
elevation myocardial infarction. Circ J. 72:1425–1429. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ota S, Nishikawa H, Takeuchi M, Nakajima
K, Nakamura T, Okamoto S, Setsuda M, Makino K, Yamakado T and
Nakano T: Impact of nicorandil to prevent reperfusion injury in
patients with acute myocardial infarction: Sigmart Multicenter
Angioplasty Revascularization Trial (SMART). Circ J. 70:1099–1104.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ikeda N, Yasu T, Kubo N, Hashimoto S,
Tsuruya Y, Fujii M, Kawakami M and Saito M: Nicorandil versus
isosorbide dinitrate as adjunctive treatment to direct balloon
angioplasty in acute myocardial infarction. Heart. 90:181–185.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
TIMI Study Group, . The Thrombolysis In
Myocardial Infarction(TIMI) trial. Phase I findings. TIMI Study
Group. N Engl J Med. 312:932–936. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gibson CM, Cannon CP, Murphy SA, Ryan KA,
Mesley R, Marble SJ, McCabe CH, Van De Werf F and Braunwald E:
Relationship of TIMI myocardial perfusion grade to mortality after
administration of thrombolytic drugs. Circulation. 101:125–130.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawai Y, Hisamatsu K, Matsubara H, Dan K,
Akagi S, Miyaji K, Munemasa M, Fujimoto Y, Kusano KF and Ohe T:
Intravenous administration of nicorandil immediately before
percutaneous coronary intervention can prevent slow coronary flow
phenomenon. Eur Heart J. 30:765–772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J,
Yang ZK, Zheng AF, Zhang X and Shen WF: Clinical benefits of
adjunctive tirofiban therapy in patients with acute ST-segment
elevation myocardial infarction undergoing primary percutaneous
coronary intervention. Coron Artery Dis. 19:271–277. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huber K, Holmes DR Jr, van't Hof AW,
Montalescot G, Aylward PE, Betriu GA, Widimsky P, Westerhout CM,
Granger CB and Armstrong PW: Use of glycoprotein IIb/IIIa
inhibitors in primary percutaneous coronary intervention: Insights
from the APEX-AMI trial. Eur Heart J. 31:1708–1716. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gibson CM, de Lemos JA, Murphy SA, et al:
TIMI Study Group: Combination therapy with abciximab reduces
angiographically evident thrombus in acute myocardial infarction: A
TIMI 14 substudy. Circulation. 103:2550–2554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rezkalla SH and Kloner RA: No-reflow
phenomenon. Circulation. 105:656–662. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reffelmann T and Kloner RA: The
‘no-reflow’ phenomenon: Basic science and clinical correlates.
Heart. 87:162–168. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galiuto L: Optimal therapeutic strategies
in the setting of post-infarct no reflow: The need for a
pathogenetic classification. Heart. 90:123–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niccoli G, Lanza GA, Shaw S, Romagnoli E,
Gioia D, Burzotta F, Trani C, Mazzari MA, Mongiardo R, De Vita M,
et al: Endothelin-1 and acute myocardial infarction: A no-reflow
mediator after successful percutaneous myocardial
revascularization. Eur Heart J. 27:1793–1798. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiu RJ, Hammerschmidt DE, Coppo PA and
Jacob HS: Anisodamine inhibits thromboxane synthesis, granulocyte
aggregation, and platelet aggregation. A possible mechanism for its
efficacy in bacteremic shock. JAMA. 247:1458–1460. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao B, Li J, Luo X, Zhou Q, Chen H and
Shi H: The role of von Willebrand factor and ADAMTS13 in the
no-reflow phenomenon: After primary percutaneous coronary
intervention. Tex Heart Inst J. 38:516–522. 2011.PubMed/NCBI
|
|
25
|
Matsumoto H, Inoue N, Takaoka H, Hata K,
Shinke T, Yoshikawa R, Masai H, Watanabe S, Ozawa T and Yokoyama M:
Depletion of antioxidants is associated with no-reflow phenomenon
in acute myocardial infarction. Clin Cardiol. 27:466–470. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang A, Chen F, Xie Y, Guo Z and Yu Y:
Protective mechanism of nicorandil on rat myocardial
ischemia-reperfusion. J Cardiovasc Med (Hagerstown). 13:511–515.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iwakura K: Modulation of individual
susceptibility to the no-reflow phenomenon after acute myocardial
infarction. Curr Pharm Des. 19:4519–4528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akai K, Wang Y, Sato K, Sekiguchi N,
Sugimura A, Kumagai T, Komaru T, Kanatsuka H and Shirato K:
Vasodilatory effect of nicorandil on coronary arterial
microvessels: Its dependency on vessel size and the involvement of
the ATP-sensitive potassium channels. J Cardiovasc Pharmacol.
26:541–547. 1995. View Article : Google Scholar : PubMed/NCBI
|
